Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-serine Augmentation of Auditory Learning in Schizophrenia
NCT03711500Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of d-serine in schizophrenia and schizoaffective disorder (4 arms), sponsored by New York State Psychiatric Institute. Primary endpoints: Plasticity Improvement (Change in Tone Matching Threshold), Mismatch Negativity and 2 more. Started Mar 2019; status: completed.
02
Drugs
d-serine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT03711500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711500.